Science & Technology
Development of Human Monoclonal Antibody Therapeutic Against Klebsiella pneumoniae Infection
Department of Defense — Defense Health Agency
Opportunity #: HT9425-23-C-0005
Award Ceiling
$1.1M
Award Floor
$1.1M
Close Date
Jul 26, 2023
Total Funding
$1.1M
Expected Awards
1
Posted Date
Feb 22, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-HT9425-23-C-0005
Description
SBIR Phase Phase II award: "Development of Human Monoclonal Antibody Therapeutic Against Klebsiella pneumoniae Infection" awarded to Technology Holding, LLC in West Valley City, Utah. Funded by Department of Defense (Defense Health Agency). Award amount: $1,099,026. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.